on Evotec AG (NASDAQ:EVTCY)
Evotec Receives $2.9 Million Grant for Drug Safety Testing Enhancement
Evotec SE has secured a $2.9 million grant from the Gates Foundation to extend its 2023 initiative on early drug safety assessments using human stem cell technology. The grant supports Evotec’s New Approach Methodologies (NAMs), crucial for predicting the potential developmental risks of new drugs. This three-year extension aims to aid global health researchers in identifying risks to fetal development more effectively.
Dr. Joanna Holbrook, Evotec's Chief Scientific Officer, emphasized the significance of identifying safety concerns early in drug development. The goal is to facilitate informed decisions about drug candidates and mitigate costly changes during clinical testing. The funding acknowledges Evotec's stem cell-based platform, known for its comprehensive human cell data and industrial-scale capability, having screened over 5,000 compounds.
Evotec's efforts align with broader New Approach Methodologies, potentially reducing reliance on animal testing while enhancing research efficiency and predictive decision-making.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news